Fri.Dec 15, 2023

article thumbnail

Cushman & Wakefield builds a foundation for enterprise-wide AI

CIO

Cushman & Wakefield has cashed in on several key IT trends over the past few years, positioning the Chicago-based firm well to weather ongoing headwinds in the commercial real estate market stirred by the COVID-19 pandemic. First there was the company’s full embrace of cloud computing, and then a pivot from project management to a product operating model.

Education 642
article thumbnail

Mastering the Art of Customer Personas for Targeted Marketing

mention

In this fast-evolving digital landscape, understanding your target audience has become more important than ever. Gone are the days when customers would respond to traditional advertising methods. In today’s age and time, every customer seeks an exquisitely tailored experience. They are hardly receptive to broad, one-size-fits-all advertisements that are aimed at everyone.

Marketing 173
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Powering digital cities

CIO

Cities of all sizes are looking for ways to deliver next-generation services that improve quality of life, increase efficiency, support sustainability, and prepare for the future — all while making the most of limited resources. That’s why municipal governments all around the world are making strategic investments in technology toward becoming a digital city.

Learning 570
article thumbnail

Responsible-First AI Governance: Addressing Ethical Concerns for Scalable Adoption

Dataversity

The world of artificial intelligence (AI) is evolving rapidly, bringing both immense potential and ethical challenges to the forefront. In this context, it is essential to remember that intelligence, when misused, can be graver than not having it at all. As AI technologies scale and become increasingly influential in various sectors, responsible governance becomes paramount […] The post Responsible-First AI Governance: Addressing Ethical Concerns for Scalable Adoption appeared first on DAT

article thumbnail

Prepare Now: 2025s Must-Know Trends For Product And Data Leaders

Speaker: Jay Allardyce, Deepak Vittal, and Terrence Sheflin

As we look ahead to 2025, business intelligence and data analytics are set to play pivotal roles in shaping success. Organizations are already starting to face a host of transformative trends as the year comes to a close, including the integration of AI in data analytics, an increased emphasis on real-time data insights, and the growing importance of user experience in BI solutions.

article thumbnail

Domo Data Never Sleeps Report Shows Latest Trends in Data Usage

Domo

The popularity of the Internet continues to grow as more people interact with digital platforms and services. The Internet has now reached 5.2 billion people, which is approximately 65 percent of the world’s population. The amount of data created, copied, captured, and consumed is expected to grow from 120 zettabytes in 2023 to 181 zettabytes by 2025.

More Trending

article thumbnail

Microsoft’s role to help sow AI success in Africa

CIO

Global spend on AI, including software, hardware, and services for AI-centric systems, is predicted to more than double between 2023 and 2026, according to the latest forecasts from IDC. This increase will see AI spend reach $154 billion in 2023 and increase to well over $300 billion by 2026. So with this monumental trend in mind, Lillian Barnard, president for Microsoft Africa, is excited to see how AI can help the continent fast track its journey toward adopting more advanced and sophisticated

Advantage 694
article thumbnail

AI in Biopharma: Use Cases and Considerations

Alpha Sense BI

Since the inception of the COVID-19 pandemic , artificial intelligence (AI) has ushered in a transformative era in drug discovery , development, and healthcare. While this technology has long been used in biopharma for small-molecule modeling and drug screening, the applications of AI now reach far beyond those initial purposes—from R&D and drug discovery to manufacturing and commercialization.